TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.

@article{Deben2016TP53AM,
  title={TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.},
  author={Christophe Deben and Vanessa Deschoolmeester and Filip Lardon and Christian C Rolfo and Patrick Pauwels},
  journal={Critical reviews in oncology/hematology},
  year={2016},
  volume={99},
  pages={
          63-73
        }
}
The p53 pathway has been extensively studied for its role in carcinogenesis. Disruption of the pathway occurs in more than half of all cancers, often leading to a worse prognosis for the patient. In recent years several compounds have been successfully developed to target and restore the p53 pathway, either by blocking the MDM2-p53 interaction, restoring wild type conformation of mutant p53, or exploiting the presence of mutant p53 by blocking DNA damage repair pathways. In this review the… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 92 REFERENCES

Similar Papers

Loading similar papers…